Regulating transcription factor RUNX1 using small molecule drugs a promising novel therapy for diseases of the retina, including advanced diabetic eye disease.

Massachusetts Lions Eye Research Fund, the E. Matilda Ziegler Foundation for the Blind, the Karl Kirchgessner Foundation, the Harvard Medical School Department of Ophthalmology and the Howard Hughes Medical Institute Medical Research Fellows Program.

Media Contact:
Suzanne Day
Media Relations Manager
Mass. Eye and Ear